Bull of the Week

AzurRx BioPharma Inc. (NASDAQ: AZRX)

AzurRx BioPharma Inc. (NASDAQ: AZRX) is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins. The company’s lead drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients suffering from cystic fibrosis and chronic pancreatitis. AzurRx has already completed two Phase 2 clinical trials for MS1819 and is currently pursuing approval through parallel monotherapy and combination therapy pathways. Continue

TraderPower Featured Stocks

• 180 Life Sciences Corp.
• AzurRx BioPharma Inc. (NASDAQ: AZRX)
• Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT)
• Canopy Rivers Inc. (TSX.V:RIV) (OTC: CNPOF)
• CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
• Creatd Inc. (NASDAQ: CRTD)
• Cybin Corp.
• DarioHealth Corp. (NASDAQ: DRIO)
• Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)
• Genprex Inc. (NASDAQ: (GNPX)
• Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)
• iClick Interactive Asia Group Ltd. (NASDAQ: ICLK)
• Knightscope, Inc.
• Net Element, Inc. (NASDAQ: NETE)
• Predictive Oncology (NASDAQ: POAI)
• Pressure BioSciences Inc. (PBIO)
• Sigma Labs Inc. (NASDAQ: SGLB)
• SRAX Inc. (NASDAQ: SRAX)
• Sustainable Green Team Ltd. (SGTM)
• The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER)
• Trxade Group Inc. (NASDAQ: MEDS)
• Wrap Technologies Inc. (NASDAQ: WRTC)